LEXICON PHARMACEUTICALS, INC. — Director's Dealing 2021

Jan 21, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK: 0001062822
Period of Report: 2021-01-11

Reporting Person: Wittouck Amaury (Director, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	32259461	Indirect
Common Stock	3516214	Indirect
Common Stock	35402689	Indirect

Footnotes

F1: On January 11, 2021, the Reporting Person became the sole member of the board of Stichting Administratiekantoor Westend (the "Stichting"), and therefore, may be deemed to beneficially own the securities reported herein. The Reporting Person disclaims beneficial ownership over the securities reported herein, except to the extent of his pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, the Reporting Person states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

F2: These securities are directly held by Artal International S.C.A.

F3: These securities are directly held by Invus Public Equities, L.P.

F4: These securities are directly held by Invus, L.P.

F5: The Reporting Person is the sole member of the board of the Stichting. The Stichting is the majority stockholder of Westend S.A. Westend S.A. is the parent company of Artal Group S.A. Artal Group S.A. is the sole stockholder of Artal International Management S.A., which is the managing partner of Artal International S.C.A. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. and through its Geneva branch is the sole stockholder of Artal Treasury Limited. Artal Treasury Limited is the managing member of Invus Public Equities Advisors, LLC. Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P.